Key result
Elevated suPAR levels at ICU admission predicted higher ICU mortality, with an odds ratio of 1.58 per doubling of suPAR, and improved risk stratification in patients with moderate organ dysfunction.
Why the study?
Soluble urokinase plasminogen activator receptor is an inflammatory biomarker and kidney disease risk factor with potential prognostic value in critically ill patients.
Do elevated suPAR levels at ICU admission predict ICU mortality, 28-day mortality, and acute kidney injury in critically ill patients?
Cohort (n=237)
No
Do elevated suPAR levels at ICU admission predict ICU mortality, 28-day mortality, and acute kidney injury in critically ill patients?
Odds Ratio: 1.58 (95% CI 1.22–2.04)
p-value: p=0.001
Elevated suPAR levels at ICU admission are a strong independent predictor of acute kidney injury and, particularly in patients with moderate organ dysfunction (SOFA ≤ 7), of ICU mortality.
Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker and risk factor for kidney diseases, with a potential prognostic value in critically ill patients. In this monocentric prospective study, we measured plasma suPAR levels immediately after ICU admission in unselected 237 consecutive patients using a turbidimetric assay. Primary objective was the prognostic value for ICU- and 28-day mortality. Secondary objectives were association with sequential organ failure assessment (SOFA) score, coagulation and inflammation markers, AKI-3 and differences in prespecified subgroups. Median suPAR levels were 8.0 ng/mL [25th-75th percentile 4.3-14.4], with lower levels in ICU survivors than non-survivors (6.7 vs. 11.6 ng/mL, p < 0.001). SuPAR levels were higher in COVID-19, kidney disease, moderate-to-severe liver disease, and sepsis. ICU mortality increased by an odds ratio (OR) of 4.7 in patients with the highest compared to lowest quartile suPAR. Kaplan-Meier overall survival estimates at 3 months were 63% and 49%, in patients with suPAR below/above 12 ng/mL (log-rank p = 0.027). Due to an observed interaction between SOFA score and suPAR, we performed a random forest method identifying cutoffs. ICU mortality was 53%, 17% and 2% in patients with a SOFA score > 7, SOFA ≤ 7 & suPAR > 8 ng/mL, and SOFA score ≤ 7 & suPAR ≤ 8 ng/mL, respectively. suPAR was a significant predictor for AKI-3 occurrence (OR per doubling 1.89, 95% CI: 1.20-2.98; p = 0.006). suPAR levels at ICU admission may offer additional value for risk stratification especially in ICU patients with moderate organ dysfunction as reflected by a SOFA score ≤ 7.
No takes yet. Share an insight, caveat, or question.
Reisinger et al. (2021) conducted a cohort in Critical illness requiring intensive care unit (ICU) admission (n=237). Elevated soluble urokinase plasminogen activator receptor (suPAR) levels vs. Lower suPAR levels was evaluated on ICU mortality (OR 1.58, 95% CI 1.22-2.04, p=0.001). Elevated suPAR levels at ICU admission predicted higher ICU mortality, with an odds ratio of 1.58 per doubling of suPAR, and improved risk stratification in patients with moderate organ dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: